Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

Intercept Pharmaceuticals Stock is Halted Today as the FDA Advisory Committee is Reviewing Obeticholic Acid as a Treatment of NASH Precirrhotic Fibrosis

May 19, 2023 0
Intercept Pharmaceuticals  Intercept Pharmaceuticals Inc (ICPT) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics aimed at treating progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). On May 19, 2023, Intercept Pharmaceuticals, announced that NASDAQ has halted trading of the company’s common stock. Today’s Meeting Today, the …

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement...

New Study from Neuvivo’s NP001: First to Link Regulation of...

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its...

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001...

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy...

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002...

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant...

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene...

CytomX Therapeutics Provided an Important Strategic Update

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven...

Vertex Pharmaceuticals and Type 1 Diabetes

An Important Reminder from Vir Biotechnology

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s...

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little...

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s...

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office...

These Dangerous World Circumstances and the Prohost Portfolio

Impacting News

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

May 26, 2023 0
Inside the Revolution In the Treatments of Untreatable Diseases We are now living a great revolution …

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

April 25, 2023 0
Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals (AVIR) announced that the U.S. FDA …

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

April 19, 2023 0
News from Innoviva That We Consider Positively Impacting and Extremely Important Innoviva, Inc. (INVA) (Innoviva), announced …

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

April 12, 2023 0
Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers …

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults

April 3, 2023 0
TG Therapeutics Positive CHMP of BRIUMVI TG Therapeutics, Inc. (TGTX), informed that the Committee for Medicinal …

An Important New Licensing Agreement Between Vertex Pharmaceuticals and CRISPR Therapeutics

March 27, 2023 0
Vertex Pharmaceuticals and Crispr Therapeutics Agreement Aims at Accelerating Vertex's Hypo immune Cell Therapies for Type …

Trick or Trade

Our Eyes Are on Reata Pharmaceuticals Today

May 25, 2023 0
Eye on Reata Pharmaceuticals Recently, Reata Pharmaceuticals (RETA) announced a setback of its chronic kidney disease …

Why the Current Interest in Ventyx Biosciences

March 7, 2023 0
The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus  We like the fact that Ventyx …

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

February 8, 2023 0
Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' …

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

February 7, 2023 0
Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel  treatments aimed at improving …

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

February 2, 2023 0
It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …
Stocks Outperforming Today

Stocks Outperforming Today

January 5, 2023 0
January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Today’s Highlights

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

June 1, 2023 0
UT Southwestern Medical Center and RenovoRx RenovoRx Inc (RNXT) announced that the University of Texas (UT) …

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

May 30, 2023 0
Amylyx Pharmaceuticals  Amylyx Pharmaceuticals (AMLX) announced an update on the ongoing review of its Marketing Authorization …

Bio-Techne ExoDx Prostate Test is More Accurate in High- and Low-Risk Patients Compared to Standard of Care

May 18, 2023 0
Prostate Cancer Prostate cancer is the most common type of cancer found in men, accounting for …

Celldex Therapeutics Presented Positive Preclinical Data from its TSLP/SCF Bispecific Antibody Program CDX-622 at AAI

May 15, 2023 0
Celldex Therapeutics Announcement Celldex Therapeutics (CLDX) announced today preclinical data from its CDX-622 bispecific antibody with …

Why CureVac Stock Traded Up in a Bad Day Market

May 8, 2023 0
CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) …

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV 

May 4, 2023 0
Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged …

Prohost Letters

Gilead Sciences – Still Way Undervalued

December 29, 2022 0
Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead …

Treating Untreatable Disease – NASH

October 13, 2022 0
Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis  The efforts spent on treating …

Shorting Biotech Firms with Solid Fundamentals

July 19, 2022 0
Prohost Comprehensive Letter #451 Shorting Biotech Firms with Solid Fundamentals Unfair shorting of promising stocks seems …

Bear Market. Bad Market. Unpredictable Market.

May 17, 2022 0
Prohost Comprehensive Letter #450 BEAR MARKET. BAD MARKET. UNPREDICTABLE MARKET. Stock market investors usually learn from …

Comprehensive Prohost Letter #449 – Reality

March 27, 2022 0
Comprehensive Prohost Letter Issues Reality The Best of words in informative texts are the smallest in …

Comprehensive Prohost Letter #448

December 22, 2021 0
Comprehensive Prohost Letter Issues Coronavirus Variant Omicron A lot has happened since the coronavirus variant Omicron …

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2023.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement